[ Repare Therapeutics raises $68M in Series A ]
Repare Therapeutics has raised $68 million in Series A funding.
Founded in 2016, Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
With this financing, Repare emerges from Versant’s Discovery Engines after an 18-month stealth period during which the company advanced its leading CRISPR-enabled synthetic lethality drug discovery platform, identified several promising oncology targets and moved multiple programs into preclinical development.
|Founder / CEO||Lloyd M. Segal|
|BDC Healthcare Venture|
|Fonds de solidarité FTQ|